Pentamethylquercetin

Pentamethylquercetin

SCHEMBL2286327

COc1cc(OC)c2c(=O)c(OC)c(-c3ccc(OC)c(OC)c3)oc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 10/20 1.00
ABCB1 P08183 6/20 1.00
ABCC1 P33527 3/20 1.00
KDM4E B2RXH2 2/20 1.00
CYP3A4 P08684 2/20 1.00
MEN1 O00255 1/20 1.00
ALDH1A1 P00352 1/20 1.00
MAPK1 P28482 1/20 1.00
KMT2A Q03164 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
ADORA3 P0DMS8 4/20 0.81
SLC22A2 O15244 1/20 0.81
SLC22A1 O15245 1/20 0.81
LMNA P02545 1/20 0.76
TP53 P04637 1/20 0.76
MAPT P10636 1/20 0.76
CASP1 P29466 1/20 0.76
CASP7 P55210 1/20 0.76
TUBB4A P04350 1/20 0.67
TUBB P07437 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pentamethylquercetin SCHEMBL30168918 1.00 ABCG2 (1.00) ABCG2ABCB1ABCC1KDM4ECYP3A4
Pentamethylquercetin SCHEMBL30168919 1.00 ABCG2 (1.00) ABCG2ABCB1ABCC1KDM4ECYP3A4
Pentamethylquercetin SCHEMBL29725289 1.00 ABCG2 (1.00) ABCG2ABCB1ABCC1KDM4ECYP3A4
Tetramethylkaempferol SCHEMBL1664159 0.90 ADORA3 (1.00) ABCG2ABCB1ABCC1KDM4ECYP3A4
SCHEMBL4286969 0.89 ABCG2 (0.87) ABCG2ABCB1ABCC1KDM4ECYP3A4
Retusin SCHEMBL29496204 0.89 ABCG2 (1.00) ABCG2ABCB1ABCC1KDM4ECYP3A4
Retusin SCHEMBL1421755 0.89 ABCG2 (1.00) ABCG2ABCB1ABCC1KDM4ECYP3A4
SCHEMBL1208084 0.88 ABCG2 (0.79) ABCG2ABCB1ABCC1KDM4ECYP3A4
SCHEMBL20464068 0.88 ADORA3 (1.00) ABCG2ABCB1ABCC1KDM4ECYP3A4
SCHEMBL29864461 0.88 ADORA3 (1.00) ABCG2ABCB1ABCC1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115248-A1 METHOD FOR PRODUCING BLACK GINGER EXTRACT AND METHOD FOR PRODUCING COMPOSITION MARUZEN PHARM CO LTD (JP) 2026-04-30 US claimed
US-12514278-B2 Tobacco-derived composition R.J. REYNOLDS TOBACCO COMPANY (US) 2026-01-06 US claimed
CN-114867486-B Composition containing black ginger extract and composition for oral administration 丸善制药株式会社 2023-05-30 CN claimed
US-20230021051-A1 Composition Containing Black Ginger Extract and Composition for Oral Administration MARUZEN PHARMACEUTICALS CO., LTD. (JP) 2023-01-19 US claimed
WO-2023276167-A1 SIRTUIN ACTIVATOR 株式会社常磐植物化学研究所 2023-01-05 WO claimed
CN-115475157-A Intestinal barrier improving agent 株式会社资生堂 2022-12-16 CN claimed
US-20220346435-A1 TOBACCO-DERIVED COMPOSITION REYNOLDS TOBACCO CO R (US) 2022-11-03 US claimed
US-11452756-B2 Composition and method for improving quantity of tear fluid, composition, treating constipation and improving skin quality TOKIWA PHYTOCHEMICAL CO., LTD. (JP) 2022-09-27 US claimed
CN-110432537-B Tobacco-derived O-methylated flavonoid compositions R.J.雷诺兹烟草公司 2022-08-19 CN claimed
US-11412775-B2 Tobacco-derived composition R.J. REYNOLDS TOBACCO COMPANY (US) 2022-08-16 US claimed
WO-2006132879-A2 SOFT GEL CAPSULES CONTAINING POLYMETHOXYLATED FLAVONES AND PALM OIL TOCOTRIENOLS SOFT GEL TECHNOLOGIES, INC. (US) 2006-12-14 WO claimed
US-6987125-B1 Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2006-01-17 US claimed
US-20060003947-A1 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols THE CIT GROUP/CREDIT FINANCE, INC. 2006-01-05 US claimed
US-20050249803-A1 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols SOFT GEL TECHNOLOGIES, INC. 2005-11-10 US claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1278417-A1 COMPOSITIONS AND METHODS OF TREATING, REDUCING, AND PREVENTING CARDIOVASCULAR DISEASES AND DISORDERS WITH POLYMETHOXYFLAVONES KGK Synergie (CA) 2003-01-29 EP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001070029-A1 COMPOSITIONS AND METHODS OF TREATING, REDUCING, AND PREVENTING CARDIOVASCULAR DISEASES AND DISORDERS WITH POLYMETHOXYFLAVONES KGK SYNERGIE (CA) 2001-09-27 WO claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050249803-A1 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols TTPA, CCNE2, PTGES ABCG2 217/4885ABCB1 353/4885ABCC1 1043/4885
US-20260115248-A1 METHOD FOR PRODUCING BLACK GINGER EXTRACT AND METHOD FOR PRODUCING COMPOSITION CYP4F8, CYP4F2, CYP4F11 ABCG2 75/4885ABCB1 159/4885ABCC1 2372/4885
US-20230021051-A1 Composition Containing Black Ginger Extract and Composition for Oral Administration CYP4F8, CYP4F2, CYP4F11 ABCG2 125/4885ABCB1 98/4885ABCC1 921/4885
US-20060003947-A1 Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols TTPA, PLA2G10, GSTO1 ABCG2 143/4885ABCB1 819/4885ABCC1 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.